Rothschild Investment LLC’s Enanta Pharmaceuticals ENTA Stock Holding History

Rothschild Investment LLC’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.76K	Sell	258 -46	-15%	-$618	﹤0.01%	2439
2026 Q1	$3.84K	Buy	304 +51	+20%	+$684	﹤0.01%	2196
2025 Q4	$3.99K	Sell	253 -12	-5%	-$152	﹤0.01%	2008
2025 Q3	$3.17K	Sell	265 -25	-9%	-$200	﹤0.01%	1953
2025 Q2	$2.19K	Buy	290 +265	+1,060%	+$1.59K	﹤0.01%	2015
2025 Q1	$138	Sell	25 -55	-69%	-$340	﹤0.01%	2912
2024 Q4	$460	Buy	80 +70	+700%	+$671	﹤0.01%	2569
2024 Q3	$104	Hold	10	–	–	﹤0.01%	2845
2024 Q2	$130	Buy	+10	New	+$135	﹤0.01%	2636

Other funds holding ENTA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CCIA

Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Rothschild Investment LLC's ENTA Position: Q2 2026 in Review

Rothschild Investment LLC reduced its Enanta Pharmaceuticals (ENTA) stake by 15% in Q2 2026, selling an estimated $618 and leaving 258 shares worth $3.76K. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Rothschild Investment LLC first reported a position in ENTA in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.99K in Q4 2025. 40 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Rothschild Investment LLC held 258 shares of Enanta Pharmaceuticals worth $3.76K as of Q2 2026.
Rothschild Investment LLC sold 46 Enanta Pharmaceuticals shares in Q2 2026, an estimated $618.
Enanta Pharmaceuticals made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2439 holding.
Rothschild Investment LLC first reported a position in Enanta Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Rothschild Investment LLC's Enanta Pharmaceuticals position peaked at $3.99K in Q4 2025.
40 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.